Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Eli Lilly

FDA Approves Eli Lilly's Jardiance In Broader Heart Patient Population

The FDA approved Eli Lilly And Co (NYSE:LLY) and partner Boehringer Ingelheim's drug, Jardiance, for expanded use in reducing the risk of death and hospitalization for all patients with heart failure. Initially approved by the FDA in 2014 for type 2 diabetes patients, the drug's use was expanded last year in some adults living with heart failure…

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Nearly 66% Of Patients Respond To Eli Lilly's Mirikizumab In Ulcerative Colitis Study

Patients with moderately-to-severely active ulcerative colitis (UC) who took Eli Lilly And Co's (NYSE: LLY) mirikizumab

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

ICER's Report Suggests Benefits Of Eli Lilly's Tirzepatide Not Better Than Other Diabetes Drugs

Institute for Clinical and Economic Review (ICER) casts doubts on Eli Lilly And Co’s (NYSE: LLY) tirzepatide, a type II diabetes candidate, about its usefulness to patients compared to the rivals.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

US FDA Advisers Say More Data Needed for Cancer Drug Tested in China

A panel of outside advisers to the US Food and Drug Administration on Thursday voted to recommend that Innovent Biologics Inc and Eli Lilly and Co be required to conduct a trial of their lung cancer drug that is applicable to the US population. Data submitted to the FDA for…

Asharq Al-Awsat

Eli Lilly Q4 Earnings Beat Estimates On Higher Demand For Trulicity, COVID-19 Therapies; Reaffirms FY22 Guidance

Eli Lilly And Co (NYSE: LLY) has

Eli Lilly: Q4 Earnings Insights

Eli Lilly (NYSE:LLY) reported its Q4 earnings results on Thursday, February 3, 2022 at 06:25 AM. Here's what investors need to know about the announcement.

A Preview Of Eli Lilly's Earnings

Eli Lilly (NYSE:LLY) is set to give its latest quarterly earnings report on Thursday, 2022-02-03. Here's what investors need to know before the announcement. Analysts estimate that Eli Lilly will likely report an Earnings Per Share (EPS) of $2.19.

inkl

Read news from The Economist, FT, and more,
with one subscription

Looking At Eli Lilly's Recent Whale Trades

Looking At Eli Lilly's Recent Whale Trades

Benzinga's options scanner just detected over 12 options trades for Eli Lilly (NYSE:LLY) summing a total amount of $597,272. At the same time, our algo caught 7 for a total amount of 518,954.

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Eli Lilly Expects FDA Rejection For Expanded Use Baricitinib For Eczema

Based on top-line efficacy results from two pivotal Phase 3 trials Eli Lilly And Co (NYSE: LLY) has decided to

Michigan AG to investigate Eli Lilly insulin prices, but state courts could prove an obstacle

Michigan Attorney General Dana Nessel plans to investigate Eli Lilly's insulin pricing but will have to first overturn Michigan court precedent in order to push forward with the probe.

Tribune News Service

What Are Whales Doing With Eli Lilly

What Are Whales Doing With Eli Lilly

A whale with a lot of money to spend has taken a noticeably bullish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 13 strange trades.

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

FDA Rescinds Authorization For Regeneron, Eli Lilly COVID-19 Antibody Treatments: Here's Why

Antibody treatments made by Regeneron Pharmaceuticals Inc (NASDAQ: REGN) and Eli Lilly And Co (NYSE: LLY) are not likely to work against the Omicron variant of COVID-19 and their emergency use authorization has been rescin

FDA halts use of antibody drugs that don't work vs. omicron

FDA halts use of antibody drugs that don't work vs. omicron

U.S. health officials say COVID-19 antibody drugs from Regeneron and Eli Lilly should no longer be used because they don't work against the omicron variant

The Independent UK

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today

If You Invested $1000 In This Stock 5 Years Ago, Here's How Much You Would Have Today

Eli Lilly (NYSE:LLY) has outperformed the market over the past 5 years by 12.31% on an annualized basis.

Get all your
news in one place.

100’s of premium titles.
One news app.

Expert Ratings For Eli Lilly

Over the past 3 months, 7 analysts have published their opinion on Eli Lilly (NYSE:LLY) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Looking Into Eli Lilly and Company's Recent Short Interest

Eli Lilly and Company's (NYSE:LLY) short percent of float has risen 4.0% since last its last report. The company recently reported that it has 6.19 million shares sold short, which is 0.78% of all regular shares that are available for trading.

Looking At Eli Lilly's Recent Whale Trades

A whale with a lot of money to spend has taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly (NYSE:LLY) we detected 11 strange trades.

The Best Health Care ETFs to Buy

Health care ETFs can provide lower volatility while diversifying across a variety of medical industries.

Get all your
news in one place.

100’s of premium titles.
One news app.

1 … 23 24 25 26

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

AstraZeneca Plc

US Food and Drug Administration

Eli Lilly and Company

Eli Lilly And Co

Regeneron Pharmaceuticals Inc

Boehringer Ingelheim

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

324,024 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play